Chief scientist Dr Limin

Dr. Limin previously served as senior vice President and President of global neurological drug development at glaxosmithkline. In 2012, it was selected into the "thousand talents plan" of the seventh batch of central innovative talents in China.

He graduated from wuhan university in 1984 with a bachelor's degree in biochemistry, and from Johns Hopkins university in 1991 with a doctor's degree. He was hired as an assistant professor in the department of neuroscience at Johns Hopkins university school of medicine in 1994, an associate professor in 1998, and a professor in 2004.

Professor limin is the founder and director of the Johns Hopkins university ion channel center. He is also the deputy director of the Johns Hopkins university high throughput biology center.

Founded in February 2016, Shanghai glidao pharmaceutical technology co., ltd. is an innovative pharmaceutical research and development company aiming at cutting-edge technologies. Since its establishment, it has successfully carried out three rounds of financing and developed rapidly with the support of investment funds. The company's research and development pipeline focuses on the neurological diseases associated with ion channels, such as pain, epilepsy, depression and neurodegenerative diseases. The company has established close cooperative relationship with domestic and foreign universities, research institutes and listed pharmaceutical groups. Litao has applied for 3 PCT patents, 9 Chinese invention patents, and obtained 2 authorization. The company has recently completed the construction of an ion channel drug research and development platform, which can detect and evaluate all ligand-gated and voltage-gated ion channels, and conduct drug screening and early safety pharmacology studies on ion channel targets.